Patents by Inventor Ricarda Finnern

Ricarda Finnern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies capable of binding to the coagulation factor XIa and uses thereof
    Patent number: 11046783
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 29, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XIA AND USES THEREOF
    Publication number: 20190284300
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 19, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
  • Antibodies capable of binding to the coagulation factor XIa and uses thereof
    Patent number: 10221247
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: March 5, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof
    Patent number: 10040866
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 7, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XIA AND USES THEREOF
    Publication number: 20180112009
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: August 30, 2017
    Publication date: April 26, 2018
    Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
  • NUCLEIC ACIDS AND HOST CELLS EXPRESSING ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XIA AND USES THEREOF
    Publication number: 20180051093
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: August 30, 2017
    Publication date: February 22, 2018
    Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
  • Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
    Patent number: 9783614
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: October 10, 2017
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straβburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jöriβen, Asako Itakura, Philberta Leung, Erik Tucker
  • ANTI-C4.4A ANTIBODIES AND USES THEREOF
    Publication number: 20170158775
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: February 6, 2017
    Publication date: June 8, 2017
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Lars LINDEN, Yong-Jiang CAO, Gabriele LEDER, Beatrix STELTE-LUDWIG, Axel HARRENGA, Ricarda FINNERN, Frank DITTMER, Anke MAYER-BARTSCHMID, Juergen FRANZ, Simone GREVEN, Jörg WILLUDA, Jan TEBBE
  • Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and uses thereof
    Publication number: 20150099298
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 9, 2015
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Leung, Erik Tucker
  • Anti-FGFR2 Antibodies and Uses Thereof
    Publication number: 20140322220
    Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: November 22, 2012
    Publication date: October 30, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
  • BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS
    Publication number: 20140050743
    Abstract: The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: January 17, 2012
    Publication date: February 20, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Frank Dittmer, Anja Buchmüller, Christoph Gerdes, Adrian Tersteegen, Mark Jean Gnoth, Lars Linden, Axel Harrenga, Joanna Grudzinska-Goebel, Mario Jeske, Martina Schäfer, Jörg Birkenfeld, Holger Paulsen, Ricarda Finnern, Anke Mayer-Bartschmid, Andrea Eicker, Simone Greven, Susanne Steinig
  • ANTI-C4.4A ANTIBODIES AND USES THEREOF
    Publication number: 20120321619
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: December 8, 2010
    Publication date: December 20, 2012
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Lars Linden, Yong-Jiang Cao, Gabriele Leder, Beatrix Stelte-ludwig, Axel Harrenga, Ricarda Finnern, Frank Dittmer, Anke Mayer-Bartschmid, Juergen Franz, Simone Greven, Jörg Willuda, Jan Tebbe
  • Diabody which specifically binds surface antigen I/II and methods of use thereof
    Patent number: 7625561
    Abstract: Common oral diseases such as periodontitis and dental caries can be prevented effectively by passive immunization. The present invention provides human single chain Fv (scFv) and diabody antibody fragments based on the binding characteristics of the murine monoclonal antibody Guy's 13. Like the parent antibody, these derivatives bind specifically to SAI/II, the surface adhesin of Streptococcus and the human diabody derivative is capable of aggregating streptococcal cells, making it a useful candidate therapeutic agent for passive immunization against oral diseases.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: December 1, 2009
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Ricarda Finnern, Rainer Fischer
  • Diabody which Specifically Binds Streptococcus Surface Antigen I/II and Methods of Use Thereof
    Publication number: 20070231321
    Abstract: Common oral diseases such as periodontitis and dental caries can be prevented effectively by passive immunization. The present invention provides human single chain Fv (scFv) and diabody antibody fragments based on the binding characteristics of the murine monoclonal antibody Guy's 13. Like the parent antibody, these derivatives bind specifically to SAI/II, the surface adhesin of Streptococcus and the human diabody derivative is capable of aggregating streptococcal cells, making it a useful candidate therapeutic agent for passive immunization against oral diseases.
    Type: Application
    Filed: April 21, 2005
    Publication date: October 4, 2007
    Applicant: FRAUNHOFFER-GESELLSCHAFT ZUR FORDERUNGDER ANGEWAND
    Inventors: Ricarda Finnern, Rainer Fischer